AlphAIAlphAI — Financial news for AI agents
rttnews.comSEP 172 min read$TLSA

Tiziana Signs MOU With KAIMRC To Advance Foralumab MS Trials; Stock Up

Tiziana Life Sciences (TLSA) signed an MOU with KAIMRC and others to advance trials of intranasal foralumab for relapsing-remitting multiple sclerosis (RRMS). The collaboration aims to evaluate foralumab's combination with anti-CD20 therapy. TLSA's stock rose 14.27% in pre-market trading. The company's stock has traded between $0.76 and $2.35 over the past year.

Original reporting
rttnews.com
Published Sep 17, 2026, 1:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 17, 2026, 2:26 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefTechnology
Primary signal
$TLSA
Bullish
medium confidence
Mentioned
$TLSA
Relevance
7/10
AlphAI data visualization · based on rttnews.com
Decision brief

The 30-second read

$TLSABullishMed
01

Why it matters

The MOU adds a new clinical arm targeting patients poorly responding to anti‑CD20 therapy, expanding the company's pipeline and partnership network.

02

Market read

First‑report of a strategic MOU that could drive short‑term price movement for TLSA and signal growing Saudi‑US biotech ties.

03

What to watch

Potential regulatory hurdles and the need for co‑funding could delay or limit the trial's impact.

Relevance 7/10Novelty 7/10Timing: pre‑market today

Background

Tiziana Life Sciences focuses on intranasal delivery of foralumab, a fully human anti‑CD3 antibody, for neuroinflammatory diseases.

Company-level read

Ticker impact

$TLSABullishMedium confidence
Context

Tiziana Life Sciences signed an MOU to run a combination trial of intranasal foralumab with anti‑CD20 therapy in RRMS patients.

Expected impact

Short‑term upside pressure as investors price in the new trial collaboration; volatility may increase.

Evidence & confidence

MOU is a fresh catalyst for a micro‑cap biotech; no data yet, so upside is speculative but material for the stock.

Market effects

Sector

May spur interest in other intranasal immunomodulators and MS biotech programs.

Regional

Highlights Saudi research institutions' role in global biotech collaborations.

Global

Limited to niche biotech sector; unlikely to affect broader indices.

Counterpoint

What could challenge this read

Without near‑term data, the MOU could be overhyped; investors may wait for trial results before committing.

Key entities

  • company
    Tiziana Life Sciences, Ltd.

    Biotech developing intranasal foralumab.

  • institution
    King Abdullah International Medical Research Center (KAIMRC)

    Saudi research center collaborating on the MS trial.

Read at source← All news

Also covered by

1 outlet

Related articles

OCT 16
$TLSAMedAI 8/10

Tiziana completes dosing in Phase 2 Alzheimer’s trial of intranasal foralumab

Tiziana Life Sciences (TLSA) completed dosing in its Phase 2 trial of intranasal foralumab for early or mild Alzheimer's, with topline data expected in Q1 2027. The trial, assessing safety, tolerability, and efficacy, includes foralumab alone and in combination with lecanemab or donanemab. Key endpoints include changes in neuroinflammation, cognitive function, and fluid biomarkers.

finance.yahoo.com1 min
SEP 30
$MDBMed

Market movers: HPE, Boeing, Salesforce, Tiziana Life

MongoDB (MDB) raised long-term growth targets, with Bank of America maintaining a Buy rating. Tiziana Life Sciences (TLSA) seeks FDA orphan drug designation for foralumab. Apple (AAPL) plans a Siri-powered smart-home hub. Salesforce (CRM) acquired Listen Labs, shares up 3.2%. Boeing (BA) won a multi-billion-dollar Navy contract. Conagra (CAG) shares fell 4.6% after Q1 revenue decline. HPE (HPE) shares rose 5% after a $1.2B order from Vultr.

proactiveinvestors.com3 min
SEP 30
$TLSAMed

Tiziana Files For Orphan Drug Designation For Foralumab In MSA

Tiziana Life Sciences (TLSA) applied to the FDA for Orphan Drug Designation for its intranasal foralumab treatment for Multiple System Atrophy (MSA). The company is conducting a Phase 2a study. Approval could offer market exclusivity and other benefits. TLSA shares were down 1.43% premarket. According to the company, foralumab is a fully human anti-CD3 monoclonal antibody.

rttnews.com1 min
SEP 30
$TLSAMed

Tiziana Life Sciences Files for Orphan Drug Designation with the FDA for Intranasal Foralumab for the Treatment of Multiple System Atrophy (MSA)

Tiziana Life Sciences (TLSA) filed for FDA Orphan Drug Designation for intranasal foralumab to treat Multiple System Atrophy (MSA), a rare neurodegenerative disease. The company is conducting a Phase 2a trial. If granted, the designation could provide market exclusivity and other benefits. Foralumab is also being studied for other neuroinflammatory conditions.

globenewswire.com2 min
SEP 30
$MUHighAI 8/10

MARKETS LIVE: Nasdaq powers ahead as cooler inflation eases Fed rate concerns

Micron (MU) may report Q4 EPS in mid-$30s due to rising DRAM/NAND prices, per Wedbush. MongoDB (MDB) raised revenue growth targets. Apple (AAPL) plans a Siri-powered smart-home hub. Boeing (BA) won a $20B Navy contract. Conagra (CAG) Q1 revenue fell 1.4% to $2.6B. HPE (HPE) secured a $1.2B order. NCLH expects Q3 results to exceed guidance. US GDP revised to 2.2% growth, core PCE inflation eased to 3.0% YoY.

proactiveinvestors.com3 min